A case of pseudomyxoma peritonei arising from a perforated intraductal papillary mucinous neoplasm that underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Yuhi YoshizakiYoshimasa GohdaFuyuki InagakiAtsuko KataokaNobuyuki TakemuraHideki MiyazakiToru IgariTomomichi KiyomatsuHideaki YanoNorihiro KokudoPublished in: Clinical journal of gastroenterology (2023)
Pseudomyxoma peritonei (PMP) of pancreatic origin arising from an intraductal papillary mucinous neoplasm (IPMN) is rare. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has been established as the optimal treatment for PMP. However, the benefits and safety of CRS with HIPEC for treating PMP of pancreatic origin remain unclear. Herein, we describe a case of PMP of pancreatic origin that was treated with CRS and HIPEC without postoperative complications. A 75-year-old woman was referred to our department. Computed tomography (CT) revealed a multilocular cystic tumor in the pancreatic tail, notable mucinous ascites in the abdominal cavity, and scalloping of the liver and spleen. CT did not reveal the appendix, and the ovaries were normal in size. The patient was diagnosed with PMP of pancreatic origin, and CRS and HIPEC were performed. Intraoperatively, the pancreatic tumor was perforated, and there was a large amount of mucinous ascites. We performed distal pancreatectomy in addition to CRS and HIPEC, with no intraoperative complications. The postoperative course was uneventful, and the patient survived after 6 months without recurrence. CRS with HIPEC may be a feasible treatment option for PMP of pancreatic origin.
Keyphrases
- computed tomography
- low grade
- minimally invasive
- positron emission tomography
- patients undergoing
- coronary artery bypass
- magnetic resonance imaging
- dual energy
- case report
- squamous cell carcinoma
- image quality
- single cell
- contrast enhanced
- radiation therapy
- risk factors
- genome wide
- rectal cancer
- combination therapy
- atrial fibrillation
- smoking cessation
- chemotherapy induced